Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
Any gender, aged at least 18 years at the time of study enrollment (signing the informed consent form).
Patients with RMS meeting the 2017 Revised McDonald Criteria. EDSS score between 0 and 7. Regular follow-up with MRI monitoring. Willingness to provide blood samples. Willingness to undergo clinical assessments (including scales and physical examinations).
\-
You may not be if
Any laboratory abnormality that, considering the subject's overall condition, is deemed to prevent the subject's continued participation in the study.
Any condition that may pose a safety risk due to participation in the study. Non-compliance with the administration of the investigational drug or study procedures
\-
Clareo Health | Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
